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Abstract
Background: An Acute Oncology Service (AOS) is paramount to providing timely and improved pathways 
of care for patients who are admitted to hospital with cancer-related problems or suspected cancer. Objective: 
To establish an AOS pilot study to decide how best to implement such a service locally. Methods: The AOS, 
which included collaboration between the oncology and palliative care teams at the Northern General Hospi-
tal in Sheffi eld, UK, ensured that the majority of oncology patients in the region received timely assessment 
by an oncologist if they became acutely unwell as a result of their cancer or its treatment. The AOS consisted 
of a thrice-weekly ward round, and daily telephone advice service. Results: We report on patient data dur-
ing the fi rst 12 months of the pilot study. Delivery of the AOS enhanced communication between the services 
and provided inter-professional education and support, resulting in earlier oncological team involvement in the 
management of patients with cancer admitted under other teams, as well as provision of advice to patients and 
their caregivers and families. Provision of the AOS shortened the mean length of hospital stay by 6 days. Two 
case studies are presented to illustrate the typical challenges faced when managing these patients. Conclusions: 
Establishment of the AOS enabled effective collaboration between the oncology and other clinical teams to 
 provide a rapid and streamlined referral pathway of patients to the AOS. Locally, this process has been supported 
by the development of acute oncology protocols, which are now in use across the local cancer network. 
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Introduction
In the UK, the incidence of the most common cancers, 
including breast, lung, colorectal and prostate cancer, is 
strongly associated with increasing age, and, therefore, 
many patients who have cancer also have other comor-
bidities [1]. Oncologists have to tailor their treatments to 
account for these other health problems to optimize care 
for individual patients. Comorbid conditions can restrict 
the types of oncological intervention offered to patients, 
and it is important to consider the balance of benefi t 
versus the potential risks of treatment for each patient. 
Chemotherapy-related toxicities, such as nausea and leth-
argy, may be common to the majority of agents, albeit 
to varying degrees. The oncology team, with the support 
of the palliative medicine team, manages these effects. 
Other side-effects are particular to specifi c drugs, such 
as the cardiac toxicity related to 5-fl uorouracil (5-FU), a 
chemotherapeutic agent widely used in the treatment of 
gastrointestinal and breast cancers. The incidence of angina 
following treatment with 5-FU is 1.2–18.0% [2], which is 
relatively common given the numbers of patients receiving 
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this drug. Serious cardiac pathology (ST-segment eleva-
tion or ventricular arrhythmias) is much less common, 
with an incidence of approximately 0.55% [3].
Acute oncology is a subspeciality, which has evolved 
relatively recently, that focuses on the prompt manage-
ment of patients who are admitted to hospital because 
of symptoms caused by their cancer or its treatment. 
This includes patients for whom a new diagnosis of can-
cer is established following admission to hospital with 
symptoms that may suggest a malignant cause, such as 
anaemia or dysphagia. The impetus behind the creation 
of this subspeciality was the fi ndings from two reports 
commissioned to assess the safety and quality of chemo-
therapy services in England; fi ndings which highlighted 
the often less-than-optimal care of such patients.
In 2008, the National Confi dential Enquiry into 
Patient Outcome and Death (NCEPOD) published the 
report of their study of patients who died within 30 days 
of receiving systemic anticancer therapies (SACT) [4]. 
One of the concerns raised surrounded the admission 
of acutely unwell oncology patients to hospitals where 
there are no, or limited, oncology services. In 42% of 
the cases reviewed, patients were admitted to a general 
medicine ward rather than a haemato-oncology unit 
after the development of complications from SACT. The 
report highlighted the importance of strengthening the 
links between oncology and general medicine to opti-
mize the management of patients who present acutely 
unwell to general medical physicians with complications 
of SACT. The question of whether it is appropriate for 
such patients to be admitted under the care of general 
physicians when things go wrong was also raised; how-
ever, any change to current working practice would 
require an expansion of the oncology workforce. 
Following this report, the National Chemotherapy 
Advisory Group (NCAG) was asked to address the con-
cerns raised by NCEPOD. Their report, published in 
August 2009, recommended, amongst other things, that 
all hospitals with an Accident and Emergency (A&E) 
department establish an Acute Oncology Service (AOS), 
with representation from A&E, general medicine, 
clinical and medical oncology, haematology, oncology 
nursing, and oncology pharmacy [5]. 
In April 2011, the peer-reviewed Acute Oncology 
Measures were published [6]. One stipulation of the 
report was that all hospitals with an A&E department 
should establish an AOS, providing a 5-day-per-week 
service to enable most of the patients to be seen by an 
oncologist within 24 hours of admission. In an attempt to 
assess the local requirements for an AOS, and to inform 
decisions about how best to implement such a service 
locally, we began an AOS pilot study at the Northern 
General Hospital (NGH) in Sheffi eld, UK, in Septem-
ber 2010. 
Acute oncology service in Sheffi eld
The Weston Park Hospital (WPH) in Sheffi eld, UK, 
is one of only four specialist cancer hospitals in the 
country, serving a population of 1.8 million in South 
Yorkshire and North Derbyshire. Almost all oncology 
services in Sheffi eld, including the delivery of radiothe-
rapy and systemic anticancer therapies, are concentrated 
at the purpose-built cancer centre at the WPH. The site 
also includes the Cancer Clinical Trials Centre where 
patients receive treatment in the context of clinical tri-
als. Satellite chemotherapy units also provide a limited 
range of SACT in the wider region. Geographically dis-
tinct from the WPH, the NGH in Sheffi eld currently has 
1,354 beds, and admitted 15,475 patients in the fi nan-
cial year ending March 31, 2011. It receives all acutely 
unwell adult patients in the city via the sole adult A&E 
department. Prior to September 2010, oncology input at 
the NGH was limited to one outpatient clinic and two 
multidisciplinary team meetings per week. There was 
no provision for the assessment of inpatients at the NGH 
by an oncologist.
In response to the NCEPOD and NCAG reports, an 
acute oncology pilot study was initiated in September 
2010 to provide dedicated oncology input for inpatients 
at the NGH. For the fi rst 7 months of the pilot study, a 
consultant clinical oncologist provided expertise via an 
acute oncology ward round for one-half day per week. 
This service was increased to two-and-a-half days per 
week in total, spread over 3 days, for the fi nal 5 months 
of the pilot study by the addition of a medical onco-
logy specialist registrar to the acute oncology team. The 
service was advertised repeatedly via email to all of the 
consultants at the NGH, with details of how to refer 
patients to the service. 
At the same time, an AOS was also established at the 
WPH, where the majority of patients on anticancer therapy 
in the region are admitted if they become acutely unwell 
as a result of their cancer or its treatment. The AOS at the 
WPH consists of a daily consultant ward round to ensure 
that all newly admitted patients are seen by a consultant 
within 24 hours of admission, and the availability of a 
consultant for telephone advice for clinicians from other 
specialities 24 hours per day, 7 days a week. 
Results
Analysis of the AOS data from the fi rst 12 months 
of the pilot study at the NGH
During the fi rst 12 months of the pilot at the NGH, 
136 patients were seen. Of these, 122 sets of notes were 
available for analysis, although a limited amount of 
information was available for some of those patients for 
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Figure 3 Relative frequency of the more common underlying primary 
tumour sites in patients with a cancer diagnosis. GI, gastrointestinal. 
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Figure 2 Age of newly diagnosed cancer patients.
whom the notes were not available. Patient outcomes 
were censored on 05/09/11. Two thirds of the patients 
were previously known to have a diagnosis of cancer 
(84/136; 62%). The remainder were newly diagnosed 
with cancer during their admission. Figures 1 and 2 
illustrate the age of the existing oncology patients and 
the newly diagnosed patients, respectively. 
Of the patients known to have a diagnosis of cancer, 
Figure 3 illustrates the relative frequency of the more 
common underlying primary tumour sites. Less than 
one-third of these patients (57/83) were on active anti-
cancer treatment at the time of admission to the NGH 
(see Figure 4). The reason for referral to the AOS could 
be broadly divided into one of four categories for more 
than 90% of the patients, namely: investigations had 
revealed new fi ndings and the admitting team required 
an opinion as to whether treatment was available; an 
opinion was sought specifi cally regarding palliative 
radio therapy (e.g. for bone metastases); the patient had 
new  symptoms which the admitting team thought might 
be due to the underlying malignancy; or the patient had 
been admitted with an unrelated problem, but general 
advice regarding the state of their underlying mali g-
nancy and/or its treatment was requested. 
Of the patients who received a new diagnosis of can-
cer during this admission, almost all (33/37; 89%) were 
diagnosed radiologically following investigations for new 
symptoms. The tumour sites involved are illustrated in 
Figure 5. The initial advice given by the AOS is shown 
in Figure 6. Just over half of these patients were unsuit-
able for active anticancer treatment and were therefore 
referred directly for best supportive care and/or palliative 
care. This was in part due to their poor performance sta-
tus, which precluded active treatment. This was in turn 
infl uenced by their age and the presence of comorbidi-
ties. Of the remainder, most were referred for palliative 
radiotherapy, or referred to the site-specifi c multidiscipli-
nary team or oncologist treating their respective tumour 
types. Of these patients, one-third ultimately went on 
to receive best supportive care only. Thus, overall, two-
thirds of the patients who received a new diagnosis of 
cancer during admission to the NGH ultimately received 
best supportive care. Figure 7 illustrates the outcomes of 
the patients seen during our study. Of those patients who 
were discharged from hospital, half had subsequently died 
at the time of analysis, with a median time from contact 
with the AOS to death of approximately 7 weeks. Of the 
patients who were not discharged, the vast majority died 
in hospital, with a median of 2 weeks from contact with 
the AOS to inpatient death. 
We assessed the impact of increasing the frequency of 
the AOS from one-half day per week to two-and-a-half 
days per week in terms of mean length of hospital stay 
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(LOS). By increasing the frequency of the service, we 
signifi cantly reduced the mean LOS by 6 days, from 26 
to 19.8 days. The average daily income received by the 
trust for the patients we saw was approximately £200 
per patient. A theoretical extension of their inpatient stay 
by 6 days would attract a much lower additional income 
of between £57 and £101 per night. In other words, an 
additional LOS by 6 days attracts little extra income for 
the trust, while costs continue to increase. 
The two case histories described below illustrate the 
typical challenges we faced when contributing to the 
management of these patients, many of whom were 
receiving care from several specialist teams in addition 
to the oncology team. 
Case study 1
A 79-year-old man was referred to the AOS by the admit-
ting general physicians on 14/07/11 and was seen on the 
same day. He was known to have metastatic malignant 
melanoma at the time of admission to the NGH, but 
was not previously under the care of an oncologist. He 
had been admitted on 12/07/11 with general deteriora-
tion, and had been found to have acute kidney injury 
(AKI) with a serum creatinine of 603 µmol/L on rou-
tine biochemistry. A computed tomography (CT) scan 
performed prior to this admission on 21/06/11 showed 
extensive pelvic nodal metastases from his melanoma, 
which were now presumed to have caused urinary tract 
obstruction resulting in AKI. Prior to the involvement 
of the AOS, the admitting team had sought the advice 
of the renal physicians as to the suitability of renal dialy-
sis for this man. It was concluded that dialysis was not 
appropriate. The admitting team then requested advice 
from the urologists regarding the use of nephrostomies. 
The urologists had given advice over the telephone, as 
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urology services are based at another hospital in the city. 
They had advised that nephrostomies were a possible 
option, but prior to insertion the patient would require 
re-imaging with a non-contrast CT scan to fi rmly esta-
blish the presumed cause of the AKI. After receiving this 
advice, the admitting team contacted the AOS for an 
opinion to help decide the best management. We discov-
ered a patient who had a performance status of 4, who 
was therefore not suffi ciently fi t to receive any systemic 
treatment for his underlying melanoma, the presumed 
cause of his AKI. It also became clear after speaking 
to the patient that he did not wish to have any further 
intervention. Our opinion was therefore that any fur-
ther investigations, and the insertion of nephrostomies, 
were not appropriate. We recommended that the team 
responsible for this man’s care discuss his medical pro-
blems and grave prognosis with the patient and his family, 
and instigate palliative care to manage any symptoms as 
appropriate. He died peacefully in hospital 6 days later. 
This case illustrates some of the complexities involved 
in healthcare decisions, which often include opinions 
from several different medical and surgical specialities. 
Obtaining an opinion from the relevant teams can be 
time-consuming, and clinicians are often obliged to 
make assessments and give opinions without the bene-
fi t of actually seeing the patient. This can lead to them 
giving their “gold-standard” advice, which is often 
not appropriate for individual patients. It then falls to 
another clinician, usually the consultant under whose 
care the patient has been admitted, to co-ordinate the 
patient’s care, and decide on a management plan for their 
patient, having noted the advice received. 
Case study 2 
A 61-year-old man not previously known to have cancer 
was referred to the AOS 7 days after his admission to the 
NGH under the care of the orthopaedic surgeons. He 
had been transferred from a local district general hos-
pital for a biopsy of a vertebral lesion, which had been 
found on a magnetic resonance imaging scan after he 
presented with back pain. On arrival at the NGH, the 
patient had normal neurological function. Whilst the 
results of the biopsy were awaited, the patient devel-
oped bilateral leg weakness and sensory loss. Surgery 
was not thought to be appropriate. He was seen by the 
AOS team, treatment with radiotherapy was discussed, 
and the patient was transferred to the WPH later that 
same day for radiotherapy, which was commenced the 
following day. Subsequent investigations did not reveal 
a primary tumour, although bone biopsies confi rmed 
metastatic adenocarcinoma. He therefore had a diagnosis 
of carcinoma of unknown primary. Following his radio-
therapy, he was deemed too unwell for chemotherapy 
and received best supportive care. He died 10 weeks 
after his initial diagnosis. 
Oncology and palliative medicine collaborative 
work in Sheffi eld 
The NGH has a palliative care hospital support team 
that aims to manage the symptoms of patients with 
potentially life-limiting conditions, including cancer. 
During the Sheffi eld AOS pilot study, the oncology and 
palliative care teams worked in collaboration. The main 
benefi t was timely communication between the services; 
which is particularly important given the poor prognosis 
of this patient group. Other advantages included inter-
profe ssional education and support. Other centres in 
Europe have also found that despite the presence of a 
hospital palliative care team, oncologists require training 
in symptom management, as they are often involved in 
the end-of-life care of patients with cancer [7]. Mansour 
et al. took a 1-day snapshot of the inpatients at the Royal 
Sussex County Hospital in Brighton, UK, to investigate 
admissions of patients with known or suspected cancer. 
Of the 30 patients admitted with complications of can-
cer or cancer treatment, 66% were only suitable for best 
supportive care, yet only 7.5% of these patients had been 
referred to the inpatient palliative care team [8].
Despite the fact that many of the patients referred to 
the AOS were deemed too unwell to receive or continue 
SACT, they and their relatives found reassurance from a 
specialist oncology opinion. Those with a pre-existing 
diagnosis of cancer had often developed longstand-
ing relationships with oncologists that they wanted to 
continue. That is, the presence of the AOS relieved psy-
chological distress. Many patients were referred by the 
AOS to the palliative care team for specialist symptom 
control and advanced care planning. Conversely, pal-
liative care specialists referred patients to the AOS for 
consideration of oncological treatment for the control of 
refractory symptoms, for example, radiotherapy for bone 
cancer pain. For those with a new diagnosis of cancer, 
the AOS perspective on potential anticancer treatment 
options and likely prognosis facilitated clinical decision-
making. Finally, effective teamwork allowed accurate, 
consistent information to be communicated to both 
patients and their families. 
Discussion
The use of chemotherapy and other SACT has increased 
dramatically over recent years, with an increase of 
approximately 60% in the amount of chemotherapy 
delivered over a 4-year period [5]. In addition to the 
chemotherapeutic agents, the development of numerous 
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targeted therapies over the last few decades has increased 
the choice and complexity of treatments available for 
many types of cancer, and in so doing, has resulted 
in more patients receiving more treatments for longer 
than was the case in the recent past. For example, sys-
temic therapies for patients with malignant melanoma 
have historically been limited by low response rates. 
Recently, new novel treatments have emerged which 
have broadened the treatment choices available. In addi-
tion to the well-established dacarbazine chemotherapy, 
ipilimumab (a CTLA-4 inhibitor), and vemurafenib (a 
BRAF-kinase inhibitor), are also available. Both drugs 
can cause serious toxicities that may present to speciali-
ties other than oncology (see Table 1). This expansion 
of the choice and availability of systemic treatment also 
brings with it the risk of complications from treatment, 
which may necessitate admission to hospital, sometimes 
under the care of general physicians, many of whom 
have little or no experience of prescribing these drugs 
or recognizing their complications. For example, many 
chemotherapeutic regimens can cause neutropenia, 
which brings the associated risk of neutropenic sepsis. 
It is imperative that patients with this potentially life-
threatening complication are treated immediately with 
intravenous broad-spectrum antibiotics to minimize the 
risk of multi-organ failure and death. Reported mor-
tality rates in patients admitted with neutropenic sepsis 
from other centres are between 2 and 10% [9–11]. In 
Sheffi eld, all patients on SACT are advised to contact 
the cancer centre at the WPH directly if they become 
unwell. Our series of patients seen at the NGH did not 
include any patients admitted with neutropenic fever, 
which implies that local policies appear to be effective in 
preventing the admission of such patients to the NGH. 
However, patients in other series who were treated 
with SACT at general hospitals are often are admitted 
via A&E [9]. Given that SACT can have wide-ranging 
side-effects, which may present to various branches of 
medicine, one of the roles of an AOS is to provide sup-
port in the management of such patients when they are 
admitted under the care of non-oncologists. 
In our experience, communication between teams is 
essential in order to minimize repetition of work and to 
establish more clearly the respective roles of the various 
clinicians contributing to the care of the patient. In the 
USA, sentinel events occurring in the healthcare settings 
are reported voluntarily, or via the complaints process, to 
the Joint Commission. When this occurs, the healthcare 
organization is required to share its root-cause analy-
sis, which, in turn, is reviewed by a Joint Commission 
clinician. Breakdown in communication is one of the 
leading root causes of medical adverse events reported to 
the Joint Commission [12]. This breakdown can occur 
between members of the same team at shift-change, or 
between members of different healthcare teams, which 
includes the transition from primary to secondary care 
settings, and back again [12]. Implementing a system to 
ensure that at the time of discharge from secondary care 
settings, patients and their families, as well as the patients’ 
primary care physician, are provided with key informa-
tion relating to recent results, diagnoses and changes in 
medication, can also reduce the risk of adverse events. 
In addition, direct communication between secondary 
and primary care regarding a new diagnosis of cancer 
in an elderly patient who is unfi t for anticancer treat-
ment, may help reduce the likelihood of readmission of 
such patients in the terminal phase of their illness. Open 
discussion about end-of-life care with these patients and 
their families may allow patients more autonomy in their 
choice regarding preferred place of death. 
Our observations also show that such communi-
cation between healthcare professionals and patients 
is often suboptimal. Directly asking the patient about 
their wishes regarding further intervention is a simple, 
Table 1 Examples of novel anticancer agents, their indications and toxicities. 
Drug Class Indications Toxicities
Bevacizumab (Avastin®) mAb Metastatic breast cancer, metastatic colorectal 
cancer, non-small-cell lung cancer, glioblastoma 
multiforme, metastatic renal cell cancer
Haemorrhage, gastrointestinal perforation, 
delayed wound healing, thromboembolism, 
hypertension, proteinuria
Cetuximab (Erbitux®) mAb Metastatic colorectal cancer, head and neck 
cancer
Infusion reactions, acneiform rash, nausea, 
diarrhoea, hair changes, sore eyes
Erlotinib (Tarceva®) EGFR, TKI Non-small-cell lung cancer Rash, diarrhoea, fatigue
Gefi tinib (IressaTM) EGFR, TKI Non-small-cell lung cancer Rash, diarrhoea, stomatitis, fatigue
Ipilimumab (YervoyTM) mAb Advanced melanoma Immune-mediated colitis, hepatitis, toxic 
epidermal necrolysis, neurological sequelae
Rituximab (MabThera®) mAb Non-Hodgkin lymphoma,
chronic lymphocytic leukaemia
Severe cytokine release syndrome, haematological 
toxicities, cardiac toxicities
Trastuzumab (Herceptin®) mAb Breast cancer, metastatic gastric cancer Heart failure, infusion reactions
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; mAb, monoclonal antibody.
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but often overlooked, way in which treatment decisions 
can be made collaboratively. In their document “Treat-
ment and care towards the end of life: good practice in 
decision making”, the General Medical Council states 
that doctors should, “Respect patients’ right to reach 
decisions with you about their treatment and care” [13]. 
During our AOS pilot study, our experience has been 
that many elderly patients who are approaching their 
end-of-life are aware of that fact, and are not distressed 
when asked to discuss their wishes regarding end-of-life 
care. As oncologists, we perhaps have more experience 
of such discussions with our patients than do doctors 
from some other specialities. However, it is the respon-
sibility of all doctors to address such issues with patients 
and their families when necessary, as it gives patients 
some autonomy at a time when treatment options are 
often limited. 
Our experience shows that patients who have cancer 
and require emergency admission to hospital, or who 
have symptoms requiring admission to hospital – which 
are subsequently found to be due to cancer – tend to be 
elderly, and have poor outcomes. Prior to the AOS pilot 
study in Sheffi eld, individual oncologists were in direct 
communication with a limited range of clinicians from 
other specialities when attending tumour site-specifi c 
multidisciplinary team meetings. During the pilot study, 
we have received referrals from numerous sources, neces-
sitating clear communication between clinical teams 
who did not previously have established links. The AOS 
provides a platform from which non-oncologists can be 
informed about the toxicities of SACT, thus encourag-
ing a more streamlined referral pathway of such patients 
to the AOS. Locally, this process has been supported by 
the development of acute oncology protocols, which are 
now in use across the local cancer network. 
In addition, patients were referred to us who had a 
newly diagnosed, often un-investigated primary, when 
historically, oncologists would only have received refer-
rals of patients who have undergone the traditional 
“work-up”, including radiological and histological 
assessment. Our data show that the majority of these 
patients are elderly, and have comorbidities, and few go 
on to receive any specifi c oncological intervention. By 
becoming involved in the care of such patients at a much 
earlier stage than would traditionally have been the case, 
we have been able to help direct their management, 
which in two-thirds of cases was towards best supportive 
care. Thus, we hope to have avoided unnecessary inves-
tigations for patients who have a poor performance status 
and are therefore not suffi ciently fi t to receive anticancer 
therapy. King and Leonard report similar fi ndings from 
The Whittington Hospital in London, UK, where the 
introduction of an AOS resulted in fewer blood tests, 
biopsies and endoscopies, and also reduced the LOS in 
these patients [14, 15]. By consulting with patients and 
their families, we have established their wishes, and have 
hopefully provided them with some autonomy as they 
approach their end-of-life. In addition to these clinical 
benefi ts, our data show that the provision of an AOS 
led to a reduction in the mean LOS of these patients. 
This, along with the savings associated with a reduction 
in unnecessary investigations in patients who are too 
unwell for active anticancer treatment, is an important 
consideration in the current fi nancial climate.
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